Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | GALK1 | P51570 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1458210 | 0.83 | ALDH1A1 (0.54) | PPARGPPARAGALK1SMN1; SMN2MAPT | |
| SCHEMBL9944357 | 0.81 | ESR1 (0.56) | ESR1PPARGPPARAGALK1LMNA | |
| SCHEMBL6558609 | 0.80 | GALK1 (0.51) | ESR1GALK1 | |
| SCHEMBL1458188 | 0.80 | LMNA (0.60) | PPARGPPARALMNAHTTSMN1; SMN2 | |
| SCHEMBL7997525 | 0.78 | SLC6A5 (0.50) | MAPTSLC6A5 | |
| SCHEMBL15662529 | 0.78 | PLAU (0.49) | ESR1PPARGPPARAGALK1LMNA | |
| SCHEMBL9944359 | 0.78 | ESR1 (0.41) | ESR1GALK1LMNAHTTPDE4A | |
| SCHEMBL3949729 | 0.78 | PPARA (0.46) | PPARGPPARALMNAHTTPLAU | |
| SCHEMBL14999454 | 0.77 | SLC6A5 (0.59) | SLC6A5 | |
| SCHEMBL9944152 | 0.77 | RORC (0.43) | PPARGPPARALMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447028-B2 | Therapeutic aryl-amido-aryl compounds and their use | KING'S COLLEGE LONDON (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | ESR1 110/4885PPARG 9/4885PPARA 12/4885 |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | ESR1 110/4885PPARG 9/4885PPARA 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.